Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Cancer medicine, 2020.

Cited by: 0|Bibtex|Views17|Links
WOS
Keywords:
ACCSCCanlotinibantiangiogenesisthird-line

Abstract:

Our findings suggest that anlotinib significantly improves PFS and OS in ACC patients and has a tendency to prolong survival in SCC patients.

Code:

Data:

Your rating :
0

 

Tags
Comments